1-3 of 3
Emilie Asselbergs
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase 2 study of carfilzomib, thalidomide, and dexamethasone as induction/consolidation therapy for newly diagnosed multiple myeloma

Clinical Trials & Observations
Pieter Sonneveld, Emilie Asselbergs, Sonja Zweegman, Bronno van der Holt, Marie Jose Kersten, Edo Vellenga, Marinus van Marwijk-Kooy, Annemiek Broyl, Okke de Weerdt, Sarah Lonergan, Antonio Palumbo, Henk Lokhorst
Journal: Blood
Blood (2015) 125 (3): 449–456.
https://doi.org/10.1182/blood-2014-05-576256
Published: 2015
Includes: Supplemental data
Journal Articles

Dose Escalation Phase 2 Trial of Carfilzomib Combined with Thalidomide and Low-Dose Dexamethason in Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma. a Trial of the European Myeloma Network

Pieter Sonneveld, MDPhD, Emilie Asselbergs, Bronno Van der Holt, PhD, Sonja Zweegman, MDPhD, Marie jose Kerstens, MD, Edo Vellenga, MD PhD, Marinus van Marwijk-Kooy, MD, Okke de Weerdt, Sarah Lonergan, MSc, Antonio Palumbo, MD, Henk Lokhorst
Journal: Blood
Blood (2014) 124 (21): 2118.
https://doi.org/10.1182/blood.V124.21.2118.2118
Published: 2014
Journal Articles

Carfilzomib Combined with Thalidomide and Dexamethasone (CTD) Is an Highly Effective Induction and Consolidation Treatment in Newly Diagnosed Patients with Multiple Myeloma (MM) Who Are Transplant Candidate

Pieter Sonneveld, MD, Emilie Asselbergs, Sonja Zweegman, MD, PhD, Bronno Van der Holt, Marie Jose Kersten, MD, PhD, Edo Vellenga, Marinus van Marwijk-Kooy, MD, Okke de Weerdt, Sarah Lonergan, MSc, Henk Lokhorst, MD, PhD
Journal: Blood
Blood (2012) 120 (21): 333.
https://doi.org/10.1182/blood.V120.21.333.333
Published: 2012